GlobeNewswire PharmaOriginal article
Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism
RegulatoryYorvipath®Positive
AI Analysis
Summary
Canada's drug agency issued a recommendation to reimburse Yorvipath (palopegteriparatide injection) with conditions for eligible adults with chronic hypoparathyroidism not adequately controlled by conventional therapy. This recommendation represents a step toward potential public reimbursement in Canada.
Outcome Details
Recommendation to reimburse with conditions
Importance:6/10
Sentiment:
0.70
reimbursementCanadaregulatorychronic hypoparathyroidismpalopegteriparatide
Read the original article
Published by GlobeNewswire Pharma on September 3, 2026 8:06 PM